Sandra Vreman Selected Research

Intranasal Administration

1/2022

Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandra Vreman Research Topics

Disease

2	COVID-19 01/2022 - 01/2020
2	Viremia 02/2021 - 06/2019
2	Cholangitis 01/2018 - 10/2014
1	Infections 01/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2020
1	Inflammation (Inflammations) 10/2014
1	Fibrosis (Cirrhosis) 10/2014

Drug/Important Bio-Agent (IBA)

1	SARS-CoV-2 spike proteinIBA 01/2022
1	VaccinesIBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	AntibodiesIBA 02/2021
1	Viral RNAIBA 01/2020
1	Viral AntigensIBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	CytokinesIBA 06/2019
1	AntigensIBA 06/2019
1	CateninsIBA 01/2018
1	Laminin (Merosin)IBA 01/2018
1	VimentinIBA 01/2018
1	Eosine Yellowish-(YS) (Eosin)IBA 10/2014
1	Prednisolone (Predate)FDA LinkGeneric 10/2014
1	Reticulin (Reticular Fiber)IBA 10/2014
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 10/2014

Therapy/Procedure

1	Intranasal Administration 01/2022